Degludec

Type: Product
Name: Degludec
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

GSK glimepiride/atorvastatin fixed dose combination tablet, which just completed Phase III clinical trials for diabetes

- Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market - a new market research report on companiesandmarkets.comDiabetes is a chronic progressive disease of the endocrine system in which, during the metabolism of carbohydrates, ... [Published PR inside - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

FDA: No Decision On CV Outcomes Trial For Afrezza

Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes “The Pink Sheet” Apr. 7, 2014Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec “The Pink Sheet” DAILY Feb. 11, 2013Degludec Review Could Lead To New CV ... [Published Health News Daily - Apr 07 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Researchers at Diabetes Institute Report New Data on Diabetes

By a News Reporter-Staff News Editor at Diabetes Week -- New research on Diabetes is the subject of a report. According to news reporting originating in La Jolla, California , by NewsRx journalists, research stated, "Insulin degludec (IDeg) is a new basal ... [Published 4 Traders - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Technical Committee denies permission to 19 clinical trial proposals recommended by NDACs

The Technical Committee and the Apex Committee, the two high-level panels to supervise the clinical trials sector, have denied clearance to several proposals of clinical trials of new drugs, including fixed dose combinations, medical devices and global ... [Published PharmaBiz - Mar 31 2014]
First reported Mar 23 2014 - Updated Mar 23 2014 - 1 reports

CHMP recommends nine new drugs

The latest set of opinions from advisors to the European Medicines Agency include recommendations to approve nine new medicines, including potential blockbuster offerings in diabetes and hepatitis C, plus a drug for a sub-type of ovarian cancer and the ... [Published Pharma Times - Mar 23 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 3 reports

Tresiba and Victoza Receive CHMP Decisions for Expanded Use

Two products for the treatment of type 2 diabetes, insulin degludec ( Tresiba ) and liraglutide ( Victoza ), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for expanded use by the European Medicines Agency's (EMA) ... [Published American Journal of Public Health - Mar 21 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Novo Nordisk unveils plans for $100m API plant

Novo Nordisk says it will invest around $100m in a new pilot facility to make the active pharmaceutical ingredients (APIs) for its pipeline of diabetes drug candidates.The 2,700 sq. m. purification facility - based at the Danish drugmaker's main Bagsvaerd ... [Published Pharmafocus - Mar 17 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Novo Nordisk will build $100m facility in Denmark

Novo Nordisk has said it plans to build a new purification plant at its R&D facility in Bagsvaerd, Denmark, to support its diabetes pipeline.The new pilot facility will expand its ability to make active pharmaceutical ingredients (APIs) for use in its ... [Published PMLive - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 2 reports

NOVO NORDISK A/S : Researchers at Novo Nordisk Target Proinsulin

By a News Reporter-Staff News Editor at Biotech Week -- Researchers detail new data in Peptide Proteins. According to news reporting out of Soborg, Denmark , by NewsRx editors, research stated, "Insulin degludec is a new-generation basal insulin with ... [Published 4 Traders - Mar 12 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Trial boost for Novo's IDegLira ambitions

Prof Stephen Gough discusses the potential of Novo Nordisk's diabetes treatment IDegLiraNovo Nordisk posted data last week demonstrating that its combination drug IDegLira avoids common side effects for diabetes treatment while still lowering blood sugar ... [Published PMLive - Mar 12 2014]
First reported Mar 11 2014 - Updated Mar 11 2014 - 1 reports

SMC decisions include U-turn on Sanofi's Zaltrap

Some patients with advanced colon cancer living in Scotland can now get routine access to Sanofi's Zaltrap (aflibercept), after cost regulators agreed that the drug's use should indeed be funded on the National Health Service after all.In July last year ... [Published Pharma Times - Mar 11 2014]
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec / insulin aspart, Revision: 2, Authorised

Entities: Insulin, Degludec, Ryzodeg

Quotes

According to the news reporters, the research concluded: "While selection of an algorithm must be based on individual patient characteristics and goals, the ability to attain good glycemic control using a simplified titration algorithm may enable patient empowerment through self-titration, improved convenience, and reduced costs."
The full indication for Victoza now reads as follows: "Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycemic"
"This is excellent news for patients with type 2 diabetes and their physicians. The update expands the options physicians have to individualise therapy for their patients and help them achieve glycaemic targets, especially if they have concerns about hypoglycaemia and weight gain" said Professor Chantal Mathieu
" Use of Tresiba in combination with GLP-1 receptor agonists in patients with type 2 diabetes mellitus"

More Content

All (21) | News (20) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
GSK glimepiride/atorvastatin fixed dose combina... [Published PR inside - Apr 14 2014]
FDA: No Decision On CV Outcomes Trial For Afrezza [Published Health News Daily - Apr 07 2014]
Researchers at Diabetes Institute Report New Da... [Published 4 Traders - Apr 02 2014]
Technical Committee denies permission to 19 cli... [Published PharmaBiz - Mar 31 2014]
CHMP recommends nine new drugs [Published Pharma Times - Mar 23 2014]
Tresiba and Victoza Receive CHMP Decisions for ... [Published American Journal of Public Health - Mar 21 2014]
Tresiba® and Victoza® Receive Positive Opinions... [Published ADVFN India - Mar 21 2014]
Tresiba® and Victoza® Receive Positive Opinions... [Published ADVFN UK - Mar 21 2014]
Pending EC decision: Tresiba, insulin degludec... [Published European Medicines Agency - Mar 21 2014]
Adocia announces positive results from BioChape... [Published PharmaBiz - Mar 21 2014]
Novo Nordisk unveils plans for $100m API plant [Published Pharmafocus - Mar 17 2014]
Novo Nordisk will build $100m facility in Denmark [Published PMLive - Mar 14 2014]
NOVO NORDISK A/S : Researchers at Novo Nordisk ... [Published 4 Traders - Mar 12 2014]
Novo Nordisk A/S : New Findings from Novo Nordi... [Published 4 Traders - Mar 12 2014]
Global Pharmaceutical & Biotechnology Outlook 2... [Published Live-PR.com - Mar 12 2014]
Trial boost for Novo's IDegLira ambitions [Published PMLive - Mar 12 2014]
SMC decisions include U-turn on Sanofi's Zaltrap [Published Pharma Times - Mar 11 2014]
Vesomni among a handful of medicines accepted f... [Published PJ Online - Mar 11 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
Novo's IDegLira shows better blood sugar contro... [Published Pharmaceutical Business Review - Dec 04 2013]
Novo Nordisk launches Tresiba for type1, type 2... [Published PharmaBiz - Sep 02 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.